Last reviewed · How we verify

NCT06181604: SYMON

Multicenter Symphony IL-6 Monitoring Sepsis ICU Study

Completed Last updated 3 August 2025
What this trial tests

trial in Sepsis in 143 participants. Completed in 12 July 2024.

Timeline
12 January 2024
Primary endpoint
12 July 2024
12 July 2024

Quick facts

Lead sponsorBluejay Diagnostics, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment143
Start date12 January 2024
Primary completion12 July 2024
Estimated completion12 July 2024
Sites7 locations across United States

Conditions studied

Sponsor

Bluejay Diagnostics, Inc.

Who can join

22 and older, any sex, with Sepsis or Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to establish an IL-6 concentration cutoff and optimal time point(s) for using Symphony IL-6 that predict 28-day mortality in patients who are admitted or are intended to be admitted to the intensive care unit (ICU) diagnosed with sepsis or septic shock.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other Bluejay Diagnostics, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06181604.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing